AtaiBeckley (ATAI) Change in Accured Expenses (2020 - 2026)
AtaiBeckley (ATAI) posted quarterly Change in Accured Expenses of -$4.1 million for Q1 2026, down 194.27% year-over-year from $4.4 million in Q1 2025, and down 194.27% quarter-over-quarter from -$1.4 million in Q1 2025.
Analysis
AtaiBeckley (ATAI) Change in Accured Expenses (2020 - 2026) Analysis & Trends
AtaiBeckley has reported Change in Accured Expenses for 6 years, with the latest figure at -$3.6 million in Q3 2025.
- Quarterly Change in Accured Expenses fell 167.62% year-over-year to -$3.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$2.1 million (up 4.54% YoY) and the FY2024 annual result came in at -$6.2 million, down 87.18% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$4.1 million, down from -$1.4 million in the prior quarter.
- The five-year high for Change in Accured Expenses was -$1.4 million in Q1 2025, with the low at -$4.1 million in Q1 2026.
- A 5-year average of -$119052.6 and a median of -$270000.0 in 2023 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2021 and 2024: Change in Accured Expenses surged 6546.73% in 2021, then slumped 404.44% in 2024.
- Over 5 years, Change in Accured Expenses stood at $2.5 million in 2021, then slumped by 248.71% to -$3.7 million in 2022, then soared by 144.5% to $1.6 million in 2023, then slumped by 246.24% to -$2.4 million in 2024, then tumbled by 51.24% to -$3.6 million in 2025.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$3.6 million, $5.7 million, and -$1.7 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | AtaiBeckley | 1.61 Bn | 1.61 Bn | - | -3.65 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.99 Mn |
| Mar 31, 2026 | -4.11 Mn |
| Sep 30, 2025 | -3.65 Mn |
| Jun 30, 2025 | 5.68 Mn |
| Jun 30, 2025 | 5.71 Mn |
| Mar 31, 2025 | -1.71 Mn |
| Mar 31, 2025 | -1.40 Mn |
| Dec 31, 2024 | -2.41 Mn |
| Sep 30, 2024 | -1.36 Mn |
| Jun 30, 2024 | 1.82 Mn |
| Mar 31, 2024 | -4.29 Mn |
| Dec 31, 2023 | 1.65 Mn |
| Sep 30, 2023 | -270,000.00 |
| Jun 30, 2023 | -1.02 Mn |
| Mar 31, 2023 | -3.69 Mn |
| Dec 31, 2022 | -3.70 Mn |
| Sep 30, 2022 | 2.60 Mn |
| Jun 30, 2022 | 606,000.00 |
| Mar 31, 2022 | 1.72 Mn |
| Dec 31, 2021 | 2.49 Mn |